Abstract 1497P
Background
Lung cancer is a malignancy with extremely high morbidity and mortality, of which non-small cell lung cancer (NSCLC) accounts for about 85%. With the advent of immunotherapy has brought survival benefit to NSCLC patients, some patients still be hard to achieving satisfactory outcomes. The link between gut microbes and immunotherapy is strong, but the role they play in NSCLC immunotherapy is unclear. The aim of this study was to investigate the relationship between gut microbial composition and the efficacy of immunotherapy in NSCLC.
Methods
Patients with advanced NSCLC receiving first-line immunotherapy were enrolled, and fresh stool samples were collected before and after 2 cycles of anti-PD-1 monoclonal antibody treatment for metagenomics sequencing and annotation using the KEGG and MetaCyc databases for subsequent differential flora analysis and functional analysis, and correlated the results with outcomes at 41 months.
Results
A total of 51 patients with advanced NSCLC treated with first-line immunotherapy were included in this study, and the relative abundance of Streptomyces, Corynebacterium, Kineosphaera, and Schaalia genus under the Actinomyces phylum was increased in the R group, and the PFS (progression-free survival time) of patients with high relative abundance of Schaalia and Corynebacterium genus was significantly longer than in those with low relative abundance. Functional analysis revealed reduced levels of glycolysis in the R group and may be due to the enrichment of Schaalia genus. The BMI and fasting glucose values of the patients may be influential factors in the relative abundance of Schaalia genus. In addition, the type of irAE occurrence was also correlated with the composition of gut microbes.
Conclusions
We have newly discovered that Schaalia genus under the Actinobacteria phylum may influence the efficacy of immunotherapy in NSCLC patients by inhibiting the level of glycolysis through affecting the level of PFP. Therefore, Schaalia flora may be a potential marker for predicting the efficacy of immunotherapy in NSCLC patients, and interfering with the levels of Schaalia or PFP is expected to be a new target to enhance the efficacy of immunotherapy in NSCLC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1478P - Circulating pre-treatment T-Cell receptor repertoire as a predictive biomarker in non-small cell lung cancer patients treated with pembrolizumab
Presenter: Elin Gray
Session: Poster session 21
1479P - Association between high baseline low density neutrophils and resistance to immunotherapy in untreated non-small cell lung cancer: Molecular characterization of low-density neutrophils
Presenter: Hugo Arasanz
Session: Poster session 21
1480P - Integrating the on-treatment mGPS improves prognostic accuracy of imaging-based staging in patients with non-small-cell lung cancer (NSCLC) treated with immune-checkpoint inhibitors
Presenter: Jonas Saal
Session: Poster session 21
1481P - Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Jose Miguel Jurado García
Session: Poster session 21
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1483P - Challenge of systemic first-line treatment of elderly lung cancer patients
Presenter: Konstantinos Ferentinos
Session: Poster session 21
1484P - Impact of concomitant KRAS/STK11 or KRAS/KEAP1 mutations on response to immune checkpoint inhibition in NSCLC: A real-world data analysis
Presenter: Louisa Hempel
Session: Poster session 21
1485P - Systemic inflammatory index dynamics at 6 weeks as an early surrogate for clinical benefit in patients with NSCLC and PD-L1≥50% expression treated with pembrolizumab: Data from the real-life practice
Presenter: Magdalena Knetki-Wroblewska
Session: Poster session 21
1486P - Treatment patterns and real-world clinical outcomes of metastatic non-small cell lung cancer patients in the immunotherapy era
Presenter: Sarah Sharman Moser
Session: Poster session 21
1487P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results
Presenter: Qi-Ming Wang
Session: Poster session 21